P
Paul J. Dyson
Researcher at École Polytechnique Fédérale de Lausanne
Publications - 863
Citations - 47684
Paul J. Dyson is an academic researcher from École Polytechnique Fédérale de Lausanne. The author has contributed to research in topics: Catalysis & Ionic liquid. The author has an hindex of 103, co-authored 810 publications receiving 42095 citations. Previous affiliations of Paul J. Dyson include University of Cambridge & University of Auckland.
Papers
More filters
Journal ArticleDOI
Bioorganometallic chemistry—from teaching paradigms to medicinal applications
TL;DR: In this tutorial review, various aspects of bioorganometallic chemistry are introduced, with the main emphasis on medicinal organometallic compounds, and rational ligand design has been shown.
Journal ArticleDOI
Homogeneous Catalysis for Sustainable Hydrogen Storage in Formic Acid and Alcohols.
Katerina Sordakis,Conghui Tang,Lydia K. Vogt,Henrik Junge,Paul J. Dyson,Matthias Beller,Gábor Laurenczy +6 more
TL;DR: In this paper, the authors describe the considerable progress that has been made in homogeneous catalysis for these critical reactions, namely, the hygienic reaction, and describe a review of the most relevant work in this area.
Journal ArticleDOI
In Vitro and in Vivo Evaluation of Ruthenium(II)−Arene PTA Complexes
Claudine Scolaro,Alberta Bergamo,Laura Brescacin,R. Delfino,Moreno Cocchietto,Gábor Laurenczy,Tilmann J. Geldbach,Gianni Sava,Paul J. Dyson +8 more
TL;DR: Results show that these ruthenium(II)-arene complexes can reduce the growth of lung metastases in CBA mice bearing the MCa mammary carcinoma in the absence of a corresponding action at the site of primary tumor growth.
Journal ArticleDOI
Metal-based antitumour drugs in the post genomic era.
Paul J. Dyson,Gianni Sava +1 more
TL;DR: What the future holds for metal-based drugs, in particular anti-metastasis drugs,In these enlightened times of the post genomic era is discussed.
Journal ArticleDOI
KP1019, a new redox-active anticancer agent--preclinical development and results of a clinical phase I study in tumor patients.
Christian G. Hartinger,Christian G. Hartinger,Michael A. Jakupec,Stefanie Zorbas-Seifried,Michael Groessl,Alexander E. Egger,Walter Berger,Haralabos Zorbas,Paul J. Dyson,Bernhard K. Keppler +9 more
TL;DR: The experimental evidence for the proposed mode of action of this coordination compound is discussed, including transport into the cell via the transferrin cycle and activation by reduction.